Results 141 to 150 of about 1,163,030 (369)

Physical activity and activity space in patients with pulmonary fibrosis not prescribed supplemental oxygen

BMC Pulmonary Medicine, 2017
Background Patients with pulmonary fibrosis (PF) have impaired quality of life, and research suggests that dyspnea and physical activity are primary drivers. As PF progresses, some patients notice the disease “shrinks their worlds”. The objective of this
Elisabeth Dowling Root, Bridget Graney, Susan Baird, Tara Churney, Kailtin Fier, Majorie Korn, Mark McCormic, David Sprunger, Tomas Vierzba, Frederick S. Wamboldt, Jeffery J. Swigris   +10 more
doaj   +1 more source

Liver inflammation and fibrosis.

Journal of Clinical Investigation, 2017
Chronic liver inflammation leads to fibrosis and cirrhosis, which is the 12th leading cause of death in the United States. Hepatocyte steatosis is a component of metabolic syndrome and insulin resistance.
Y. Koyama, D. Brenner
semanticscholar   +1 more source

Ovarian Function Restoration with Biomimetic Scaffold Incorporating Angiogenic Molecules and Antioxidant in Chemotherapy‐Induced Perimenopausal Model

Advanced Healthcare Materials, EarlyView.
This study developed a biomimetic scaffold incorporating PDRN and melatonin to restore ovarian function in chemotherapy‐induced premature ovarian insufficiency, enhancing cell survival, folliculogenesis, and hormone normalization, while improving fertility rates and offspring in a mouse model, offering a promising strategy for ovarian function ...
Da‐Seul Kim, Dong Seok Jeong, So‐Yeon Park, Ji‐Won Jung, Jeoung Eun Lee, Jun‐Kyu Lee, Seung‐Woon Baek, Dong Ryul Lee, Dong Keun Han   +8 more
wiley   +1 more source

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and Mycobacterium abscessus pulmonary disease

European Clinical Respiratory Journal
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is
Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke, Ieuan E S Evans   +10 more
doaj   +1 more source

Factors Influencing the Radiological Progression Rate of Progressive Massive Fibrosis [PDF]

, 1956
A. L. Cochrane, R. G. Carpenter
openalex   +1 more source

Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.

Gastroenterology, 2018
BACKGROUND & AIMS Little is known about the natural course of nonalcoholic fatty liver disease (NAFLD) with advanced fibrosis. We describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in ...
E. Vilar‐Gomez, Luis Calzadilla‐Bertot, Vincent Wai‐Sun Wong, M. Castellanos, Rocio Aller-de la Fuente, Mayada Metwally, M. Eslam, Licet Gonzalez-Fabian, M. Alvarez-Quiñones Sanz, Antonio Felix Conde-Martin, B. de Boer, D. McLeod, Anthony Wing Hung Chan, N. Chalasani, J. George, L. Adams, M. Romero‐Gomez   +16 more
semanticscholar   +1 more source

An In Situ Curing, Shear‐Responsive Biomaterial Designed for Durable Embolization of Microvasculature

Advanced Healthcare Materials, EarlyView.
NeoCast is a next‐generation, solvent‐free, non‐adhesive liquid embolic designed for indications where deep occlusion is desired (e.g., tumors and chronic subdural hematoma). This novel agent offers ideal embolic properties: injectability, controllability, excellent visibility, and biocompatibility.
Quynh P. Pham, Jeffrey V. Groom II, Chander Sadasivan, David J. Fiorella, David C. Madoff, Lee‐Jae Guo, Michael Fornaciari, Courtney Guertin, Craig Wiltsey, Lee Core, Jonathan Merlo, William Wustenberg, Renu Virmani, Adam S. Arthur, Robert S. Langer, George M. Whitesides, Upma Sharma   +16 more
wiley   +1 more source

On the Pathology of the Morbid State Commonly Called Chronic Bright's Disease with Contracted Kidney. (“Arterio-Capillary Fibrosis.”) [PDF]

, 1872
William Gull, Henry G. Sutton
openalex   +1 more source

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Hepatology, 2018
The aim of this study was to evaluate cenicriviroc (CVC), a dual antagonist of CC chemokine receptor types 2 and 5, for treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis (LF).
S. Friedman, V. Ratziu, S. Harrison, M. Abdelmalek, G. Aithal, J. Caballería, S. Francque, G. Farrell, K. Kowdley, A. Craxì, K. Simon, L. Fischer, Liza Melchor-Khan, Jeffrey D. Vest, B. Wiens, P. Vig, S. Seyedkazemi, Z. Goodman, V. Wong, R. Loomba, F. Tacke, A. Sanyal, E. Lefebvre   +22 more
semanticscholar   +1 more source

Engineering the Future of Restorative Clinical Peripheral Nerve Surgery

Advanced Healthcare Materials, EarlyView.
What if damaged nerves could regenerate more effectively? This review unveils cutting‐edge strategies to restore nerve function, from biomaterial scaffolds and bioactive molecules to living engineered tissues. By accelerating axonal regrowth, preserving Schwann cells, and enhancing connectivity, these approaches are reshaping nerve repair—offering new ...
Justin C. Burrell, Zarina S. Ali, Eric L. Zager, Joseph M. Rosen, Mykhailo M. Tatarchuk, D. Kacy Cullen   +5 more
wiley   +1 more source